

**In the Claims:**

Material inserted is indicated by underlining and material deleted is indicated by strike-out  
(strike-out).

1. Canceled.
2. (Currently amended) An isolated nucleic acid which ~~codes for~~ encodes the  $\alpha$  chain of a human T cell receptor, a single chain T cell receptor or a soluble T cell receptor fragment ~~and, wherein~~ said nucleic acid comprises a CDR3 region having a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence ~~coding for the~~ which encodes an amino acid sequence (~~SEQ ID NO: 23~~)

~~YCL(X<sub>1</sub>...X<sub>n</sub>)SARQLTF~~

in which ~~X<sub>1</sub>...X<sub>n</sub> represents a sequence of 3-4 amino acids, wherein the amino acid~~  
~~sequence X<sub>1</sub>...X<sub>n</sub> is selected from the group consisting of: the~~  
~~amino acid sequences~~

YCL VGG SARQLTF (SEQ: ID NO: 46),

YCL VLSG SARQLTF (SEQ: ID NO: 47),

YCL ATG SARQLTF (SEQ: ID NO: 48),

YCL VSG SARQLTF (SEQ: ID NO: 49),

YCL DSG SARQLTF (SEQ: ID NO: 50),

YCL VVSG SARQLTF (SEQ: ID NO: 51),

YCL ALAG SARQLTF (SEQ: ID NO: 52),

DU  
not  
cancel  
7/24/2003

YCL APSG SARQLTF (SEQ. ID NO: 53)

and YCL VGR SARQLTF (SEQ. ID NO: 54), and

(b) a nucleotide sequence which ~~codes for~~ encodes an amino acid sequence with an equivalent recognition specificity; for a peptide component of a T cell receptor ligand, as achieved with a T cell receptor comprising a CDR3 region ~~with~~ having the amino acid sequence of SEQ. ID NO. 23, ~~for the peptide component of the T cell receptor ligands~~ Y C L (X<sub>1</sub> . . . X<sub>n</sub>) S A R Q L T F (SEQ. ID NO: 23); wherein the CDR3 region's amino acid sequence is at least 90% identical with ~~the an~~ amino sequence of set forth in (a); and wherein the T cell receptor comprising a CDR 3 region ~~with~~ having an amino acid sequence of SEQ. ID NO: 23 specifically binds kidney carcinoma cells.

3. Canceled.
4. (Currently amended) ~~A Nucleic acid as claimed in~~ The nucleic acid of claim 2, wherein the amino acid sequence ~~X<sub>1</sub> . . . X<sub>n</sub>~~ is selected from the group consisting of ~~amino acid sequences~~ VGG (SEQ. ID NO: 46), VLSG (SEQ. ID NO: 47) and ATG (SEQ. ID NO: 48).
5. (Currently amended) A vector, wherein ~~it said vector~~ contains at least one copy of a the nucleic acid ~~as claimed in one of the claims 1 to 4 of claim 2.~~
6. (Currently amended) An isolated cell, wherein ~~it said cell~~ expresses a the nucleic acid ~~as claimed in claim 2 or 4 of claim 2.~~
7. (Currently amended) A cell, wherein ~~it said cell~~ is transformed with a the nucleic acid ~~as claimed in one of the claims 1 to 4 or with a vector as claimed in claim 5 of claim 2.~~
- 8-25. Canceled.
26. (Currently amended) A pharmaceutical composition which contains as an active component a nucleic acid as claimed in ~~one of the claims 2 or 4~~ claim 2, or a cell as claimed in claim 6 or 7

optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.

27-44. Canceled.

45. (Previously amended) An isolated nucleic acid of claim 2 wherein the nucleic acid is purified.

46. (Previously amended) A nucleic acid as claimed in claim 2 wherein the CDR3 region is (a).

47. Canceled.

48. (New) A cell, wherein said cell is transformed with the vector of claim 5.

49. (New) A pharmaceutical composition which contains as an active component a cell as claimed in claim 48 optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.